Prasad Kulkarni on the Covishield vaccine
eClinicalMedicine in conversation with - Een podcast door The Lancet Group
Categorieën:
Prasad Kulkarni, Medical Director of the Serum Institute of India, discusses his recent phase 2/3 trial on the Covishield vaccine published in eClinicalMedicine, as well as its implications for COVID vaccine development in general. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv
